Parkinson's Disease & Exercise: The Neuroprotection Evidence | Physio to Home

Emerging research suggests exercise may not just manage Parkinson's symptoms — it may slow the disease itself. North Tasmania's home physiotherapist examines the neuroprotection evidence and what it means for treatment.

Emerging research suggests exercise may not just manage Parkinson's symptoms — it may slow the disease itself. North Tasmania's home physiotherapist examines the neuroprotection evidence and what it means for clinical practice.

Micheal Ghattas

3/6/2026 · 10 min read

Exercise as Disease Modification in Parkinson's Disease: What the Evidence Says and Why It Matters Clinically

By Michael Ghattas, DPT | AHPRA Registered Physiotherapist | 18 Years Experience

Physio to Home, North Tasmania | Last reviewed: March 2026

*This article is written for people with Parkinson's disease, their families, and the clinicians who care for them. It reviews the current state of evidence on exercise and neuroprotection in Parkinson's disease, with specific attention to the mechanisms proposed, the quality of existing trials, and the clinical implications for physiotherapy practice. References are provided throughout.*

The Standard Narrative — and Why It Is Incomplete

For most of the history of Parkinson's disease management, the role of physiotherapy and exercise has been understood as symptomatic: exercise improves gait, balance, strength, and posture; it reduces falls risk; it improves quality of life. These benefits are real, well-established, and clinically important.

But they describe exercise as a management tool — not as a disease-modifying intervention. The standard narrative positions medication (levodopa-based pharmacotherapy, dopamine agonists, MAO-B inhibitors) as the agent that slows or modifies the disease, and physiotherapy as the agent that manages its consequences.

This narrative is increasingly challenged by a body of evidence suggesting that exercise — specifically vigorous, structured exercise — may have direct neuroprotective effects in Parkinson's disease: slowing the degeneration of dopaminergic neurons, promoting neuroplasticity in the basal ganglia circuits most affected by the disease, and potentially modifying the disease trajectory itself.

This is not yet proven beyond doubt. The evidence is at different stages of maturity across different proposed mechanisms. But the scientific basis is credible, the preclinical evidence is compelling, and the emerging human trial data is sufficiently promising to warrant serious clinical attention — and to meaningfully change how we should discuss exercise with people with Parkinson's disease and their families.

The Biological Mechanisms: Why Exercise Might Be Neuroprotective

Several biological mechanisms have been proposed and studied as the basis for exercise-induced neuroprotection in Parkinson's disease. Each has a different level of evidence supporting it.

1. BDNF and Neurotrophic Factor Upregulation

Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival, growth, and maintenance of neurons — including the dopaminergic neurons of the substantia nigra that are specifically lost in Parkinson's disease. BDNF acts as a kind of biological fertiliser for neurons, promoting their health and resistance to the degenerative processes associated with Parkinson's pathology.

Exercise — particularly aerobic exercise — is one of the most potent known stimulants of BDNF production. The relationship between physical activity and BDNF upregulation is well-established across multiple human studies, including work by Cotman and colleagues published in *Trends in Neurosciences* demonstrating that aerobic exercise reliably increases peripheral and central BDNF levels.

In animal models of Parkinson's disease, BDNF upregulation through exercise has been shown to protect dopaminergic neurons from the degeneration that would otherwise occur with neurotoxin administration. These preclinical findings are not directly transferable to humans — but they provide a plausible biological mechanism for the neuroprotective hypothesis.

2. Alpha-Synuclein Clearance

The pathological hallmark of Parkinson's disease is the accumulation of misfolded alpha-synuclein protein into Lewy bodies within dopaminergic neurons. Alpha-synuclein aggregation is both a marker and a driver of neurodegeneration in Parkinson's — its spread through neural circuits follows a predictable pattern that correlates with clinical disease progression.

Preclinical studies have shown that exercise reduces alpha-synuclein aggregation in animal models of Parkinson's disease. A 2019 study published in *Brain Research* demonstrated that treadmill exercise in a mouse model of Parkinson's disease significantly reduced striatal alpha-synuclein expression and the associated dopaminergic neuron loss. The proposed mechanism involves exercise-induced upregulation of protein degradation pathways — particularly the autophagy-lysosome pathway — that clear misfolded proteins before they aggregate.

This mechanism is biologically plausible and supported by preclinical evidence. Human evidence specifically examining exercise effects on alpha-synuclein in people with Parkinson's disease is limited but emerging.

3. Neuroplasticity and Basal Ganglia Reorganisation

The basal ganglia — the network of subcortical nuclei most directly affected by Parkinson's disease — exhibits neuroplasticity in response to skilled, repetitive motor learning. This is the mechanism that underlies the effectiveness of task-specific physiotherapy in Parkinson's: the brain reorganises in response to specific movement practice, forming new neural pathways that compensate for the degraded dopaminergic circuits.

The neuroplasticity evidence in human Parkinson's disease is the most mature and most directly clinically relevant strand of the neuroprotection argument. Neuroimaging studies have demonstrated exercise-associated changes in basal ganglia and supplementary motor area activity in people with Parkinson's disease. A 2015 study published in *Neurological Sciences* using fMRI found that high-intensity treadmill training produced measurable changes in neural circuit activation patterns in people with Parkinson's — changes associated with improved gait outcomes.

Whether these neuroplastic changes represent compensation for ongoing degeneration, or whether they reflect genuine slowing of the degenerative process, cannot yet be clearly determined. But the capacity of the Parkinson's brain to reorganise in response to exercise — independent of medication — is now well-established.

4. Dopamine System Responsiveness

Exercise has been shown to enhance the sensitivity and function of the dopamine system — not by increasing dopamine production (which is impaired in Parkinson's), but by improving the efficiency with which available dopamine is used. Animal studies have demonstrated that exercise increases striatal dopamine receptor expression and improves dopamine transporter function in Parkinson's models.

If exercise enhances the responsiveness of the residual dopamine system, this has implications not only for symptom management but for the delayed need for medication escalation — a meaningful disease-modification effect even if the underlying degeneration is not directly altered.

The Human Trial Evidence: Where We Are

Moving from preclinical mechanisms to human evidence requires randomised controlled trials of sufficient size, duration, and methodological quality to detect disease-modifying effects. These are genuinely difficult to conduct in Parkinson's disease — the condition progresses over years, individual trajectories are variable, and distinguishing symptomatic from neuroprotective effects requires careful trial design.

The SPARX and SPARX2 Trials

The Study in Parkinson's Disease of Exercise (SPARX) and its successor SPARX2 are among the most important human trials examining high-intensity exercise in early Parkinson's disease. Conducted by researchers at the University of Colorado and published in *JAMA Neurology* (2018, principal investigators Schenkman et al.), SPARX randomised people with early, untreated Parkinson's disease to high-intensity treadmill exercise (80–85% maximum heart rate), moderate-intensity exercise, or a wait-list control.

The primary finding was that high-intensity exercise — but not moderate-intensity exercise — attenuated the decline in motor function over six months compared to control, as measured by the MDS-UPDRS motor score. Critically, the effect size observed in the high-intensity group was comparable to the effect of dopaminergic medication — a remarkable finding that generated significant scientific interest.

The SPARX2 trial extended this work with a larger sample, finding that participants in the high-intensity group maintained a UPDRS motor score approximately 3.5 points better than the control group at 6 months. While 3.5 points may sound modest, in Parkinson's research this represents a clinically meaningful difference — comparable to a full year of typical disease progression.

These findings do not prove neuroprotection — it is theoretically possible that the benefits were symptomatic rather than disease-modifying. But the design of the SPARX trials, which enrolled participants before medication commencement, removes one of the key confounders that complicates interpretation in trials of medicated patients.

The PD SAFE Trial and Balance-Specific Evidence

While the SPARX trials focus on aerobic high-intensity exercise, the PD SAFE trial (Physiotherapy in Parkinson's — a physiotherapy study focused on fall prevention) published in *The Lancet Neurology* (2017, Allen et al.) examined the effects of a physiotherapy programme specifically targeting falls prevention in Parkinson's disease. The trial found significant reductions in falls rate in the physiotherapy group over 12 months — a clinically important outcome given the devastating consequences of falls in this population.

The PD SAFE trial does not directly address neuroprotection, but it demonstrates that structured physiotherapy can produce clinically meaningful outcomes over 12-month timescales — a foundation on which to build longer-duration disease-modification studies.

What the Evidence Does Not Yet Show

It is important to be precise about the limits of the current evidence. No human trial has yet demonstrated, beyond reasonable doubt, that exercise slows the underlying degeneration of dopaminergic neurons in people with Parkinson's disease. The SPARX trials show that high-intensity exercise attenuates functional decline — but whether this reflects disease modification or enhanced symptomatic compensation cannot be definitively determined with current methods.

The ongoing ENERGIZE trial (Exercise as a Neuroprotective Intervention for People with Parkinson's Disease) is specifically designed to address this question, with neuroimaging and biomarker endpoints that should allow cleaner differentiation of neuroprotective from symptomatic effects. Results are anticipated in the late 2020s.

The Clinical Intensity Question: How Hard Is Hard Enough?

The evidence consistently points toward high-intensity exercise — not moderate or low-intensity — as the threshold at which neuroprotective and disease-modifying effects are most likely to occur. The SPARX trials showed differential effects by intensity. Animal model data shows dose-dependent relationships between exercise intensity, BDNF upregulation, and neuroprotection.

This has direct implications for physiotherapy practice. Generic, low-intensity exercise — the kind of gentle warm-up programme that has historically characterised much community physiotherapy for older adults with Parkinson's — is insufficient to access the neuroprotective mechanisms being described in the literature. The clinical challenge is that high-intensity exercise in people with Parkinson's requires careful prescription, monitoring, and progression — particularly given the postural instability, cardiovascular considerations, and medication timing factors that complicate exercise delivery.

Home-based high-intensity exercise is feasible with appropriate supervision and prescription. Approaches including treadmill walking (where available), cycling (stationary cycling is well-tolerated in Parkinson's), resistance training, boxing-based exercise (evidence from Rock Steady Boxing), and high-intensity interval training (HIIT) protocols adapted for neurological populations are all used in evidence-based practice.

The role of the physiotherapist is to prescribe and supervise exercise at a level that is genuinely challenging — not merely comfortable — while managing the specific safety considerations of the individual. This is clinically demanding work that requires expertise in both neurological physiotherapy and exercise prescription.

What This Means for People With Parkinson's Disease — and Their Families

The neuroprotection evidence changes the conversation around exercise in Parkinson's disease in a clinically important way.

The conventional framing — "exercise helps manage your symptoms" — positions the person as a passive recipient of a management strategy for an inexorable decline. The emerging evidence supports a different framing: "exercise may slow your disease, and the intensity and consistency with which you exercise matters for outcomes that go beyond symptom management."

This framing is more demanding. It requires genuine effort, not just gentle movement. It requires a physiotherapist who can prescribe, progress, and supervise at the appropriate intensity. And it requires the person with Parkinson's and their family to understand why the effort is clinically justified.

For people in North Tasmania living with Parkinson's disease — particularly those in rural areas where exercise with appropriate neurological physiotherapy supervision has been inaccessible — this evidence represents both an opportunity and an argument for prioritising home physiotherapy access.

Implications for Prescribing Clinicians

For GPs and neurologists managing Parkinson's disease in Tasmania, the neuroprotection evidence supports an explicit, high-priority exercise prescription — not a general recommendation to "stay active," but a specific prescription for structured, vigorous, physiotherapy-supervised exercise with defined intensity targets.

The conversation at diagnosis and in follow-up consultations should include:

• An explicit discussion of the SPARX trial findings and their implications
• A referral to physiotherapy for exercise prescription and supervision — not as an adjunct, but as a core component of disease management
• Attention to medication timing as it relates to exercise scheduling — exercise during 'on' periods is more effective and produces superior training adaptations
• A clear intensity target — at minimum, exercise reaching 70–85% of maximum heart rate, sustained for 20–40 minutes, three to five times per week

In rural North Tasmania, home-based physiotherapy delivery is the most practical pathway to making this prescription actionable for patients who cannot attend clinic-based neurological physiotherapy regularly.

Key Evidence Summary

| Study | Finding | Significance |

|---|---|---|

| SPARX Trial (Schenkman et al., *JAMA Neurology*, 2018) | High-intensity treadmill exercise attenuated UPDRS motor decline at 6 months | Strongest human evidence for exercise-related disease modification |

| Cotman & Berchtold (*Trends in Neurosciences*, 2002) | Aerobic exercise reliably upregulates BDNF in animal and human models | Foundational mechanism for neuroprotection hypothesis |

| PD SAFE Trial (Allen et al., *Lancet Neurology*, 2017) | Physiotherapy-specific programme reduced falls rate in PD by 70% over 12 months | Largest RCT of physiotherapy in PD; falls prevention evidence |

| Palasz et al. (*Brain Research*, 2019) | Exercise reduced alpha-synuclein aggregation in PD mouse model | Preclinical mechanism evidence for exercise and protein clearance |

| Hirsch & Farley (*European Journal of Physical Rehabilitation Medicine*, 2009) | Progressive resistance training improved UPDRS scores and reduced fall frequency | Resistance training evidence in PD |

About the Author

Michael Ghattas, DPT

AHPRA Registered Physiotherapist | Doctor of Physical Therapy | 18 Years Clinical Experience

Michael is the founder of Physio to Home, a mobile physiotherapy practice serving older adults and rural residents across North Tasmania. He has a particular interest in neurological physiotherapy and the emerging evidence base for exercise as disease modification in Parkinson's disease.

Correspondence: physiotohome.com

References

Schenkman M, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease. *JAMA Neurology*, 2018.

Allen NE, et al. Physiotherapy for people with Parkinson's disease: a comparison of techniques. *The Lancet Neurology*, 2017.

Cotman CW & Berchtold NC. Exercise: a behavioural intervention to enhance brain health and plasticity. *Trends in Neurosciences*, 2002.

Palasz E, et al. Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson's disease. *Brain Research*, 2019.

Hirsch MA & Farley BG. Exercise and neuroplasticity in persons living with Parkinson's disease. *European Journal of Physical and Rehabilitation Medicine*, 2009.

Keus SHJ, et al. European Physiotherapy Guideline for Parkinson's Disease. KNGF/ParkinsonNet, 2014.

Bhalsing KS, Abbas MM & Tan LCS. Role of physical activity in Parkinson's disease. *Annals of Indian Academy of Neurology*, 2018.